Researchers Studying CMT1B, CMT2A, CMT4A, CMT4C, Others

A large-scale study, supported in part by MDA, seeks to determine the natural history (general disease course) of four subtypes of Charcot-Marie-Tooth disease (CMT), with particular emphasis on correlations between genetic mutations and symptoms. The four subtypes are CMT1B, CMT2A, CMT4A and CMT4C.

Another goal of the study is to assess how well newly developed scales to measure CMT progression — known as the CMT Pediatric Scale and the Minimal Dataset — measure disease progression.

In addition, the investigators are seeking people with any other form of CMT, whether or not they know their specific subtype, for possible inclusion in later studies.

The natural history study is being jointly funded by MDA and the National Institute of Neurological Disorders and Stroke (NINDS).

Neurologist and molecular geneticist Michael Shy, a longtime MDA research grantee at Wayne State University in Detroit, is the principal investigator on this study, which is expected to enroll 3,000 people.

Participants must meet genetic and other criteria

For the natural history study of CMT1B, CMT2A, CMT4A and CMT4C, prospective participants must have:

  • a diagnosis of CMT;
  • a mutation in the MPZ gene (for CMT1B); or
  • a mutation in the MFN2 gene (for CMT2A); or
  • a close relative with one of these mutations and signs and symptoms of CMT; or
  • two mutations in the GDAP1 gene (for CMT4A); or
  • two mutations in the SH3TC2 gene (for CMT4C); and
  • meet other study criteria.

For possible enrollment in future CMT studies, prospective participants can have any form of CMT and do not need to know their subtype.

Genetic testing, in general, is not paid for by the study. Exceptions may be made in some cases.

To participate in the CMT natural history study or future studies

Contact the study coordinators listed below for additional information and registration.

United States

Maryland

Johns Hopkins University, Baltimore
Contact: Andrea N. Kelley
Email: akelle12@jhmi.edu
Phone: (443) 287-0627

Michigan

Wayne State University, Detroit
Contact: Lisa Rowe
Email: lrowe@med.wayne.edu
Phone: (313) 577-1689

New York

University of Rochester
Contact: Janet Sowden
Email: janet_sowden@urmc.rochester.edu
Phone: (585) 275-1267

Pennsylvania

Children's Hospital of Philadelphia
Contact: Donnette Paris
Email: paris@email.chop.edu
Phone: (267) 426-7167

University of Pennsylvania, Philadelphia
Contact: Meryl Candor
Email: meryl.candor@uphs.upenn.edu
Phone: (215) 349-5313

 

Washington

University of Washington, Seattle
Contact: Corrie Smith, MS, CGC
Email: corrieo@u.washington.edu
Phone: (206) 598-3462

International

Australia

The Children's Hospital at Westmead
Contact: Natalie Gabrael
Email: natalig1@chw.edu.au
Phone: +61 2 9845 1904

Italy

C. Besta Neurological Institute, Milan
Contact: Chiara Marchesi
Email: chiara.marchesi@istituto-besta.it
Phone: +39-02 2394 3001

United Kingdom

National Hospital for Neurology and Neurosurgery, London
Contact: Jacky Molyneaux
Email: j.molyneaux@ion.ucl.ac.uk
Phone: +44 207 380 6852


For more information

For more information on this study, see Natural History Evaluation of Charcot-Marie-Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C and Others. You also can access this study by entering its number — NCT01193075 — into the search box at ClinicalTrials.gov.

For more on CMT, see In Focus: Charcot-Marie-Tooth Disease: Streamlined diagnostic procedures, better data collection, a new clinical trials network and new laboratory research are the foundations of MDA's CMT program.

Disease: 
Link: 
GUID: 
19 726
Time Stamp: 
1 320 939 147
Thumbnail: 
http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/CMT%20kid%2C%20Michael%20Shy_0.jpg
Node Type: 
Quest News